731 related articles for article (PubMed ID: 17237840)
1. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
Brown AJ
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
[TBL] [Abstract][Full Text] [Related]
4. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.
Sprague SM; Coyne D
Clin J Am Soc Nephrol; 2010 Mar; 5(3):512-8. PubMed ID: 20133492
[TBL] [Abstract][Full Text] [Related]
5. The role of vitamin D in vascular calcification in chronic kidney disease.
Wolisi GO; Moe SM
Semin Dial; 2005; 18(4):307-14. PubMed ID: 16076354
[TBL] [Abstract][Full Text] [Related]
6. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D treatment in chronic kidney disease.
Andress DL
Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D analogs as therapeutic agents: a clinical study update.
Wu-Wong JR; Tian J; Goltzman D
Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
[TBL] [Abstract][Full Text] [Related]
10. [Pathogenesis of secondary hyperparathyroidism and renal bone disease].
Ito H; Kinugasa E
Clin Calcium; 2004 May; 14(5):720-5. PubMed ID: 15577032
[TBL] [Abstract][Full Text] [Related]
11. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
Yaginuma T; Yamamoto H
Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
[TBL] [Abstract][Full Text] [Related]
12. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
13. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease.
Wolf M; Thadhani R
Semin Dial; 2005; 18(4):302-6. PubMed ID: 16076353
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D analogs: therapeutic applications and mechanisms for selectivity.
Brown AJ; Slatopolsky E
Mol Aspects Med; 2008 Dec; 29(6):433-52. PubMed ID: 18554710
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
16. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
Hudson JQ
Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
[TBL] [Abstract][Full Text] [Related]
17. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
[TBL] [Abstract][Full Text] [Related]
18. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
19. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
Daisley-Kydd RE; Mason NA
Pharmacotherapy; 1996; 16(4):619-30. PubMed ID: 8840368
[TBL] [Abstract][Full Text] [Related]
20. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
